Search results for: 'Role of Artificial Intelligence in Drug Discovery and Development'

Artificial Intelligence (AI) has emerged to be one of the most essential technologies to develop machine intelligence. The technology has advanced significantly over the ages to empower applications and machines to learn from its own experiences and perform autonomously. Technology evolution in the AI space is continuously driving the development o...

Enterprise digitalization and surging adoption of IoT applications have led to voluminous amounts of complex structured and unstructured data that require processing to draw meaningful insights. A Frost & Sullivan voice of customer (VOC) global survey on artificial intelligence (AI) finds that 43% of enterprises list data-centricity as a key busine...

This Frost & Sullivan research examines the growing need for artificial intelligence (AI) services to help businesses meet key goals and objectives, as well as the strategic position of public cloud service providers to develop and launch successful AI capabilities for customers. The report discusses the importance of public cloud providers in the ...

In this report, Frost & Sullivan examines the role of AI in the telecommunications services industry. Due to declining revenue from core telecom services, telecommunications service providers (telcos) are broadening their operations and leveraging AI to transform telecom services and create significant business value. We identify telcos using A...

The medical imaging and informatics industry is evolving, with vendors launching new products and solutions every other day. As the reimbursement environment transitions from fee-for-service to value-based payment, vendors business models and value propositions are changing. New evidence on the use of specific imaging techniques is influencing chan...

This project provides an overview of the effects of generative AI (Gen AI) on the healthcare and life science industry and numerous growth opportunities, including how it could overcome regulatory and cybersecurity obstacles, address the build-borrow-buy conundrum, and impact the value chain of pharmaceutical companies, medical device developers, p...

This research service focuses on the United States (US) Department of Defense (DoD) artificial intelligence (AI) contracting information for research, development, test, and evaluation (RDT&E); procurement; and services. The analyst has segmented contracting data by military department and overall leading firms. The data and insight provided are ca...

25 Apr 2022  |  North America  |  Frost Radar

Frost Radar™: Artificial Intelligence-enabled Drug Discovery, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

Pharmaceutical drug discovery and development has been suffering from declining success rates with new molecules primarily because of poor external validity of preclinical models and lack of efficacy of the molecule in terms of the intended disease indication. Drug success rates continue to be in the range of only 1 in 10 that enters clinical phase...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) encompasses insights across advances in targeted neurological therapies, cancer treatments, and AI-powered drug development. The TOE also features innovators for treatment of metabolic diseases such as obesity and heart failure.The Life Science, Health & Wellnes...